Binding-protein resistance
The analogue is used to study IGF-1 receptor activity when normal sequestration by IGF-binding proteins is greatly reduced.
P—21 • Engineered IGF signaling profile
IGF1-LR3(Long R3 insulin-like growth factor-I)
An engineered IGF-1 analogue used mainly in laboratory systems to study amplified receptor signaling, binding-protein resistance, cell growth, metabolism, and endocrine feedback.
Name
IGF1-LR3
Also known as Long R3 IGF-I or LR3 IGF-I
- Scientific classification
- 83-amino-acid IGF-1 analogue with a 13-amino-acid N-terminal extension and an arginine substitution at position 3
- Library family
- Hormonal
- Regulatory status
- Not FDA approved; distinct from FDA-approved recombinant human IGF-1 (mecasermin)
Compound overview
A laboratory analogue designed to loosen one of the natural controls on IGF-1 signaling.
Natural IGF-1 circulates with IGF-binding proteins that help regulate its availability. IGF1-LR3 was engineered with a 13-amino-acid extension and a substitution at position 3 that greatly reduces binding-protein affinity while preserving activity at the IGF-1 receptor.
Researchers use this difference to separate receptor effects from binding-protein control. Cell studies have often found the analogue more active than native IGF-1 in growth and DNA-synthesis experiments, particularly when binding proteins limit the native signal.
Animal findings are more complicated than a simple growth narrative. Studies have reported tissue-specific changes alongside suppression of endogenous growth hormone, IGF-1, IGF-binding proteins, insulin, or food intake, showing that feedback, species, dose, and model can substantially change the response.
Recent work has focused partly on how to produce and characterize recombinant IGF1-LR3, including a 2023 yeast-expression study. This advances laboratory production science, but it does not provide evidence of a safe or effective human use. Controlled human studies establishing clinical benefit, dosing, or long-term safety are absent.
Because IGF signaling can support cell proliferation, sustained or poorly controlled activation requires caution. In one tumor-bearing mouse model, LR3 IGF-I limited muscle loss while accelerating tumor growth, and laboratory prostate-cancer cells showed increased telomerase activity after exposure. These findings do not prove the same outcome in people, but they underscore why laboratory potency should not be presented as a health benefit.
Recombinant production
Newer research is improving expression and characterization methods for laboratory IGF-1 and LR3 IGF-1 materials.
Human safety and translation
There is no established controlled human evidence defining clinical benefit, safe exposure, or long-term consequences.
Mechanism under study
IGF-1 receptor signaling with reduced binding-protein control
IGF1-LR3 preserves IGF-1 receptor activity while its engineered structure changes how strongly it is buffered by IGF-binding proteins.
IGF-1 receptor
The analogue engages IGF-1 receptor signaling involved in cellular growth, survival, metabolism, and feedback regulation.
Binding-protein escape
Reduced affinity for several IGF-binding proteins can leave more analogue available to interact with receptors in experimental systems.
PI3K-AKT and MAPK
Downstream pathways include PI3K-AKT and MAPK signaling, with outcomes that vary by tissue, species, timing, and disease model.
Greater laboratory activity does not establish greater usefulness or safety in people. It may also reduce a natural buffering mechanism that normally limits IGF signaling.
Current research areas
Questions under investigation
- How cells respond when IGF-binding proteins are bypassed
- How muscle, bone, cartilage, and intestinal cells use IGF signals
- How growth hormone, insulin, and IGF feedback interact
- How production methods affect purity and biological activity
- Whether sustained growth signaling is safe and whether laboratory findings translate to people
Evidence summary
A useful laboratory tool with major translational gaps
- Receptor-signaling tool: IGF1-LR3 helps researchers examine IGF-1 receptor activity with less interference from IGF-binding proteins.
- Cell-growth models: The analogue is used to study proliferation, survival, and DNA synthesis under controlled laboratory conditions.
- Tissue-response models: Animal and cell studies explore how different tissues respond to a stronger or less-buffered IGF signal.
- Endocrine feedback: Research can reveal how external IGF activity changes endogenous growth hormone, insulin, IGF-1, and binding-protein systems.
- Production science: Recombinant-expression studies help improve how the analogue is produced and characterized for research.
No controlled human studies establish muscle growth, recovery, anti-aging, metabolic, or other clinical benefits from IGF1-LR3. Reduced binding-protein control may also remove part of the body's normal buffering system.
Educational notice
Education, not usage guidance.
This profile is provided for scientific education only. It is not medical advice, performance-enhancement guidance, dosing information, or instructions for IGF1-LR3 use. IGF1-LR3 is not FDA approved and is not the same substance as FDA-approved mecasermin. No controlled human evidence establishes its safety, effectiveness, or appropriate exposure. Hypoglycemia and excessive growth signaling are pathway-related concerns rather than proven, quantified risks for IGF1-LR3, and tumor-model findings warrant particular caution. Research-market materials should not be assumed to match substances used in published studies.
Key scientific referencesComing soon
A curated primary-source reference list will be added during the next educational expansion.